After this period, cells were incubated separately with increasing concentrations of 5-fluorouracil
or phenylpropanoids (0.
The most common adverse reactions (>50%) in patients with advanced colorectal cancer receiving FUSILEV in combination with 5-fluorouracil
were diarrhea, nausea and stomatitis.
Although bisabololoxide A at 10 [micro]M does not significantly potentiate the inhibitory action of 5-fluorouracil
on the growth of K562 cells, the compound may reduce the dose of 5-fluorouracil
, that decreases the incidence of side effect.
Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil
and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer.
Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil
on vascular endothelium: a scanning microscopy evaluation.
Patients with advanced colorectal cancer who had previously been treated with irinotecan and 5-fluorouracil
were randomized to one of three study arms: FOL-FOX4 alone, 10 mg/kg of bevacizumab given intravenously once every 2 weeks, or both regimens.
Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil
Scientists don't understand how the two drugs work together, but they speculate that levamisole stimulates the immune system and somehow interacts with 5-fluorouracil
to destroy cancer cells.
About My5-FU Saladax's first commercially available test for innovative dose management; My5-FU measures levels of 5-fluorouracil
(5-FU), a widely used chemotherapy drug used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors.
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil
sibthorpioides is comparable to that of the common antitumor agent 5-fluorouracil
William Steward, professor of oncology at the University of Leicester (England), led a phase I/II trial in which 35 patients were treated with escalating doses of the experimental compound, called PTK787/ZK, along with FOLFOX-4 chemotherapy (oxaliplatin, 5-fluorouracil
, and leucovorin), a standard combination therapy for advanced colorectal cancer.